Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:EWTXNASDAQ:KNTENASDAQ:STOK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.70+4.5%$0.83$0.50▼$4.67$38.27M0.7643,667 shs318,977 shsEWTXEdgewise Therapeutics$15.94-1.1%$16.81$5.12▼$20.69$1.48B0.14918,649 shs607,514 shsKNTEKinnate Biopharma$2.65-0.4%$2.60$1.04▼$7.18$125.13M1.38418,678 shs2.81 million shsSTOKStoke Therapeutics$11.69+0.3%$9.29$3.35▼$16.40$541.29M0.77976,950 shs564,531 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics-5.02%-8.24%-18.09%+18.95%-82.91%EWTXEdgewise Therapeutics+2.94%+2.94%+0.69%+2.42%+107.07%KNTEKinnate Biopharma0.00%0.00%0.00%+10.42%+1.34%STOKStoke Therapeutics+3.64%-0.51%+79.38%+140.91%+43.77%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.6919 of 5 stars3.41.00.04.21.21.71.3EWTXEdgewise Therapeutics1.5951 of 5 stars3.51.00.00.02.62.50.0KNTEKinnate Biopharma4.3558 of 5 stars3.05.00.04.70.03.31.3STOKStoke Therapeutics4.1238 of 5 stars4.41.00.04.82.41.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,292.86% UpsideEWTXEdgewise Therapeutics3.00Buy$31.2095.73% UpsideKNTEKinnate Biopharma2.00Hold$8.15207.45% UpsideSTOKStoke Therapeutics2.78Moderate Buy$19.6367.88% UpsideCurrent Analyst RatingsLatest STOK, CARA, EWTX, and KNTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.004/17/2024EWTXEdgewise TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.004/16/2024EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.004/11/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/4/2024STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/26/2024STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $17.003/26/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $22.003/26/2024STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/26/2024STOKStoke TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.82N/AN/A$1.05 per share0.67EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AKNTEKinnate BiopharmaN/AN/AN/AN/A$5.06 per shareN/ASTOKStoke Therapeutics$8.78M61.65N/AN/A$3.57 per share3.27Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)EWTXEdgewise Therapeutics-$100.16M-$1.58N/AN/AN/AN/A-32.06%-30.16%5/9/2024 (Estimated)KNTEKinnate Biopharma-$116.27M-$2.78N/AN/AN/AN/A-62.31%-54.72%5/9/2024 (Estimated)STOKStoke Therapeutics-$104.70M-$2.37N/AN/AN/AN/A-56.86%-41.59%5/2/2024 (Estimated)Latest STOK, CARA, EWTX, and KNTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2024Q4 2023STOKStoke Therapeutics-$0.62-$0.60+$0.02-$0.60$3.70 million$2.80 million3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/22/2024Q4 2023EWTXEdgewise Therapeutics-$0.44-$0.47-$0.03-$0.47N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AKNTEKinnate BiopharmaN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43EWTXEdgewise TherapeuticsN/A19.5019.50KNTEKinnate BiopharmaN/A10.8010.80STOKStoke TherapeuticsN/A6.996.99OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%EWTXEdgewise TherapeuticsN/AKNTEKinnate Biopharma80.89%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%EWTXEdgewise Therapeutics31.95%KNTEKinnate Biopharma41.70%STOKStoke Therapeutics12.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.67 million52.36 millionOptionableEWTXEdgewise Therapeutics8893.11 million63.36 millionOptionableKNTEKinnate Biopharma8447.22 million27.53 millionOptionableSTOKStoke Therapeutics11046.30 million40.61 millionOptionableSTOK, CARA, EWTX, and KNTE HeadlinesSourceHeadlineEarnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Declinezacks.com - April 25 at 11:07 AMStoke Therapeutics (NASDAQ:STOK) Trading 4.9% Higher marketbeat.com - April 24 at 3:36 PMStoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4%marketbeat.com - April 22 at 1:54 PMSkorpios Trust Sells 3,600,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stockamericanbankingnews.com - April 20 at 4:16 AMStoke-on-Trent to host its first comedy festivalyahoo.com - April 19 at 8:27 AMStoke City predicted starting XI vs Plymouth as Steven Schumacher weighs up old boys' claimsmsn.com - April 19 at 8:27 AMProtest outside Stoke-on-Trent Crown Court - here's whymsn.com - April 19 at 8:27 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stockinsidertrades.com - April 19 at 6:35 AMStoke Therapeutics (NASDAQ:STOK) Trading 4.5% Higher marketbeat.com - April 18 at 2:47 PMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerfinance.yahoo.com - April 17 at 8:40 AMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerbusinesswire.com - April 17 at 8:00 AMBridport 2-0 Stoke Gabriel & Torbay Police: Match reportbridportnews.co.uk - April 17 at 1:25 AMThe focus inside the Stoke City changing room ahead of Plymouth Argyle and 'biggest game of season'msn.com - April 17 at 1:25 AMHow killers planned Stoke DPD worker's 'public execution' before celebrating with blood-soaked weaponsstokesentinel.co.uk - April 17 at 1:25 AMStoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 12 at 9:48 AMQ2 2024 Earnings Forecast for Stoke Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:STOK)marketbeat.com - April 12 at 6:24 AMBuy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioningmarkets.businessinsider.com - April 12 at 12:09 AMStoke Therapeutics' (STOK) Buy Rating Reaffirmed at Needham & Company LLCmarketbeat.com - April 11 at 8:32 AMStoke Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.54) Per Share (NASDAQ:STOK)marketbeat.com - April 11 at 7:26 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 6 at 2:43 AMStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferencebusinesswire.com - April 4 at 4:30 PMStoke Therapeutics (NASDAQ:STOK) Shares Up 5.1%marketbeat.com - April 4 at 2:24 PMAssessing Stoke Therapeutics: Insights From 6 Financial Analystsmarkets.businessinsider.com - April 4 at 2:16 PMStoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Cantor Fitzgeraldmarketbeat.com - April 4 at 10:16 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Edgewise TherapeuticsNASDAQ:EWTXEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Kinnate BiopharmaNASDAQ:KNTEKinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.Stoke TherapeuticsNASDAQ:STOKStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.